Acorn Capital Advisors
Latest statistics and disclosures from Acorn Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TERN, CGON, URGN, PBYI, TRVI, and represent 71.26% of Acorn Capital Advisors's stock portfolio.
- Added to shares of these 6 stocks: JBIO (+$11M), CADL, URGN, KPTI, LONA, Bioatla.
- Started 2 new stock positions in KPTI, JBIO.
- Reduced shares in these 7 stocks: QTTB, ACRV, JSPR, CRDF, X4 Pharmaceuticals, HELP, CGON.
- Sold out of its position in ACRV.
- Acorn Capital Advisors was a net buyer of stock by $20M.
- Acorn Capital Advisors has $352M in assets under management (AUM), dropping by 19.21%.
- Central Index Key (CIK): 0002054410
Tip: Access up to 7 years of quarterly data
Positions held by Acorn Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Acorn Capital Advisors
Acorn Capital Advisors holds 22 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Terns Pharmaceuticals (TERN) | 26.2 | $92M | 1.7M | 52.72 |
|
|
| Cg Oncology (CGON) | 21.8 | $77M | 1.1M | 67.74 |
|
|
| Urogen Pharma (URGN) | 8.6 | $30M | +15% | 1.7M | 17.98 |
|
| Puma Biotechnology (PBYI) | 7.5 | $26M | 4.1M | 6.39 |
|
|
| Trevi Therapeutics (TRVI) | 7.3 | $26M | 2.1M | 11.93 |
|
|
| Candel Therapeutics (CADL) | 4.9 | $17M | +35% | 3.5M | 4.92 |
|
| Bicara Therapeutics (BCAX) | 3.6 | $13M | 643k | 19.89 |
|
|
| Onkure Therapeutics Class A Com (OKUR) | 3.3 | $12M | 2.8M | 4.14 |
|
|
| Jade Biosceinces Com New (JBIO) | 3.1 | $11M | NEW | 787k | 14.05 |
|
| Protara Therapeutics Com Stk (TARA) | 2.6 | $9.1M | 1.8M | 5.21 |
|
|
| Verastem (VSTM) | 2.2 | $7.8M | 1.5M | 5.30 |
|
|
| Helus Pharma Com Stk (HELP) | 2.1 | $7.4M | -2% | 1.5M | 4.80 |
|
| Leonabio Common Stock (LONA) | 1.9 | $6.5M | +26% | 635k | 10.28 |
|
| Aura Biosciences (AURA) | 1.1 | $4.0M | 596k | 6.69 |
|
|
| Aadi Bioscience (WHWK) | 1.1 | $3.9M | 1.1M | 3.45 |
|
|
| Cardiff Oncology (CRDF) | 0.8 | $2.9M | -10% | 1.8M | 1.62 |
|
| Q32 Bio (QTTB) | 0.6 | $2.0M | -36% | 315k | 6.42 |
|
| Karyopharm Therapeutics Common Stock (KPTI) | 0.5 | $1.6M | NEW | 288k | 5.57 |
|
| Jasper Therapeuritc (JSPR) | 0.4 | $1.2M | -20% | 1.4M | 0.88 |
|
| X4 Pharmaceuticals | 0.3 | $967k | -14% | 234k | 4.13 |
|
| Bioatla | 0.2 | $865k | +11% | 5.4M | 0.16 |
|
| Vyne Therapeutics (VYNE) | 0.0 | $855.000000 | 1.4k | 0.60 |
|
Past Filings by Acorn Capital Advisors
SEC 13F filings are viewable for Acorn Capital Advisors going back to 2024
- Acorn Capital Advisors 2026 Q1 filed May 15, 2026
- Acorn Capital Advisors 2025 Q4 filed Feb. 17, 2026
- Acorn Capital Advisors 2025 Q3 filed Nov. 17, 2025
- Acorn Capital Advisors 2025 Q2 filed Aug. 14, 2025
- Acorn Capital Advisors 2024 Q4 restated filed May 19, 2025
- Acorn Capital Advisors 2025 Q1 restated filed May 19, 2025
- Acorn Capital Advisors 2025 Q1 filed May 15, 2025
- Acorn Capital Advisors 2024 Q4 amended filed May 7, 2025